BridgeMD
New treatment option for Interstitial Lung Disease (ILD)
Official title Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial
ClinicalTrials.gov ID: NCT07486206
What this study is testing
- What it's testing
- The OPTIMIZE-ILD-2 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated follow-up pathway on patients with established interstitial lung disease (ILD). In routine clinical practice, follow-up workflows for ILD are frequently fragmented, requiring multiple hospital visits for pulmonary function tests, laboratory analysis, treatment administration, and consultations with various specialists, which increases the burden for both patients and caregivers.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years.
- Established diagnosis of interstitial lung disease (ILD).
- Currently receiving antifibrotic therapy, immunosuppressive therapy, or both, as part of routine ILD care.
- Under active follow-up at the participating ILD center.
- Able to attend the required follow-up procedures included in the study visit.
You likely can't join if
- Inability to complete the coordinated follow-up visit for non-medical reasons (e.g., logistical impossibility).
- Clinical instability or acute illness interfering with planned follow-up procedures (such as respiratory infection, suspected ILD exacerbation, acute...
- Participation in another treatment clinical trial that may alter visit frequency or follow-up structure.
- Cognitive impairment preventing informed consent or completion of questionnaires.
- Patient refusal to participate or refusal to allow data collection.
See the full eligibility criteria
- Age ≥ 18 years.
- Established diagnosis of interstitial lung disease (ILD).
- Currently receiving antifibrotic therapy, immunosuppressive therapy, or both, as part of routine ILD care.
- Under active follow-up at the participating ILD center.
- Able to attend the required follow-up procedures included in the study visit.
- Able to provide informed consent.
- Inability to complete the coordinated follow-up visit for non-medical reasons (e.g., logistical impossibility).
- Clinical instability or acute illness interfering with planned follow-up procedures (such as respiratory infection, suspected ILD exacerbation, acute heart failure, or other acute conditions).
- Participation in another treatment clinical trial that may alter visit frequency or follow-up structure.
- Cognitive impairment preventing informed consent or completion of questionnaires.
- Patient refusal to participate or refusal to allow data collection.
The study team makes the final eligibility decision.
Where it's taking place
- Granollers, Barcelona, Spain
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Granollers, Barcelona, Spain. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.